Bendroflumethiazide-d7

• Description:

  Bendroflumethiazide-d7 (Bendrofluazide-d7) is deuterium labeled Bendroflumethiazide (HY-B1363) . Bendroflumethiazide (Bendrofluazide) is an orally available diuretic. Bendroflumethiazide inhibits the electroneutral sodium-chloride symporter located in the apical membrane of the early segment of the distal convoluted tubule and can effectively lower blood pressure. Bendroflumethiazide is used in the study of hypertension and edema. Bendroflumethiazide has an antidiuretic effect in diabetes insipidus[1][2][3].

• Product Name Alternative:

  Bendrofluazide-d7

• UNSPSC:

  12352005

• Target:

  Isotope-Labeled Compounds; NKCC

• Related Pathways:

  Membrane Transporter/Ion Channel; Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Smiles:

  O=S(C1=C(C(F)(F)F)C=C(C2=C1)NC(C([2H])([2H])C3=C([2H])C([2H])=C([2H])C([2H])=C3[2H])NS2(=O)=O)(N)=O

• Molecular Formula:

  C15H7D7F3N3O4S2

• Molecular Weight:

  428.46

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Tamargo J, et al. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother. 2014 Mar;15 (4) :527-47.|[3]Grønbeck L, et al. Mechanism of antidiuresis caused by bendroflumethiazide in conscious rats with diabetes insipidus. Br J Pharmacol. 1998 Feb;123 (4) :737-45.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported